Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

NGNatalie GalaninaATAung TinCGCassandra Gillespie

Discussion

Loading...

Member takes

Overview

Real-world data shows ctDNA enhances risk stratification and clinical outcomes in lymphoma, indicating its potential for personalized monitoring.

Key Points

  • This research aims to evaluate the prognostic utility of ctDNA in both aggressive and indolent lymphomas for risk stratification.
  • Retrospective analysis of ctDNA testing in 148 patients with B-cell (129) and T-cell lymphoma (19).
  • Patients received various therapies, including CAR-T, analyzed with a tumor-informed 16-plex assay.
  • Plasma samples collected at baseline, during therapy, and at end-of-treatment to assess ctDNA status.
  • ctDNA detection at baseline was 95.7% across subtypes, with 100% in indolent lymphomas.
  • ctDNA positivity at end-of-treatment correlated with worse event-free survival (HR: 7.33).
  • Among CAR-T patients, 82% were ctDNA-positive pre-infusion, with 55% achieving post-infusion clearance.

Cite This Study

Galanina et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d708https://doi.org/10.1182/blood-2025-281
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1ctDNA for MRD Assessment is Prognostic and Predictive in Newly Diagnosed and Relapsed/Refractory Lymphoma2026
  2. 2Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy2024 · 20 citations
  3. 3Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL)2025
  4. 4Prognostic value of circulating tumor DNA (ctDNA) for recurrence detection across solid tumors: A real-world meta-analysis.2026
  5. 5Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma2024 · 10 citations